Bracco Imaging’s ultrasound contrast agent SonoVue has been cleared by China's National Medical Products Administration for use in assessing female infertility.
SonoVue is used in hysterosalpingo contrast sonography, a contrast-enhanced ultrasound procedure that can help identify potential causes of female infertility related to blockage of the fallopian tubes or uterine abnormalities. Fallopian tube conditions, such as blockages, scarring, or other damage, are a leading cause of infertility, contributing up to 35% of cases of infertility among women in China, Bracco said.
